By: IPP Bureau
Last updated : July 16, 2026 9:08 am
The acquisition of Integrace further strengthens the firm's healthcare investment strategy and reflects growing investor confidence in India's branded formulations market
Global private equity firm Warburg Pincus has acquired Integrace Private Limited, a domestic pharmaceutical formulations company focused on orthopedics and gynecology, marking a significant investment in India's fast-growing branded generics market.
The acquisition underscores Warburg Pincus' strategy of building scaled, therapy-focused pharmaceutical platforms in India, where rising healthcare awareness, increasing incomes and expanding access to quality healthcare continue to drive long-term market growth.
Integrace has established a portfolio of more than 20 brands across high-growth therapeutic segments and has built relationships with over 45,000 healthcare professionals across India through its science-led marketing approach. The company has developed a strong specialist prescriber base in orthopedics and gynecology.
As part of the transaction, industry veteran Rehan Khan, former Managing Director of MSD India and Abbott India, has been appointed Chief Executive Officer of Integrace to lead the company's next phase of growth in partnership with Warburg Pincus.
Commenting on the acquisition, Himanshu Nema, Managing Director, Warburg Pincus, said, "Integrace has built an exceptional foundation with a differentiated portfolio in orthopedics and gynecology, a strong position in high-growth therapeutic segments and trusted relationships with specialists. This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India. We are excited to partner with Rehan and the team on this journey."
Rehan Khan, Chief Executive Officer, Integrace, said India's pharmaceutical market offers significant long-term opportunities, particularly in women's health and orthopedic therapies.
"Integrace has built a strong platform through its differentiated portfolio, deep scientific strengths and trusted relationships with healthcare professionals. With Warburg Pincus' business-building expertise and healthcare investing experience, we look forward to building a scaled therapy-focused domestic formulations platform in India," he said.
As part of the deal, existing investors True North and Temasek will make a complete exit from the company.
Satish Chander, Partner, True North, said, "We are proud to have partnered with the Integrace team as they built it into a strong quality healthcare company that established a deep and respectable position amongst specialists through its science-based marketing practices. We wish Rehan, Warburg Pincus and the entire team continued success in the next phase of growth."